Evidence map›Paper›PMID 38353122›Full record

ReviewDisease models & mechanisms2024

Stem cell modeling of nervous system tumors.

Frank B Furnari, Corina Anastasaki, Shan Bian, Howard A Fine, Tomoyuki Koga, Lu Q Le, Fausto J Rodriguez, David H Gutmann

Open access · goldAbstract readReview
In one paragraph

Review in Disease models & mechanisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Frank B FurnariDepartment of Medicine, University of California, San Diego, San Diego, CA 92037, USA.ORCID 0000-0003-1909-4361
Corina AnastasakiDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-9928-6488
Shan BianInstitute for Regenerative Medicine, School of Life Sciences and Technology, Tongji University, 200070 Shanghai, China.
Howard A FineDepartment of Neurology, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-6169-5702
Tomoyuki KogaDepartment of Neurosurgery, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-8330-117X
Lu Q LeDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-2817-5382
Fausto J RodriguezDivision of Neuropathology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
David H GutmannDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-3127-5045
Washington University in St. Louis · USCornell University · USThe University of Texas Southwestern Medical Center · USTongji University · CNUniversity of California, Los Angeles · USUniversity of California San Diego · USUniversity of Minnesota · US

Funding

Project 4: Secondary Cancers Among NF1 Cancer SurvivorsU54CA196519 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI KEVIN M. SHANNON · 2015 to 2026
$26.9M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Defining the Mechanistic Basis for Neurofibromatosis-1 Nervous System Disease HeterogeneityR35NS097211 · NINDS · WASHINGTON UNIVERSITY · PI GUTMANN, DAVID H · 2017 to 2024
$5.7M
Transcriptional Function of Krox20 in Development and TumorigenesisR01CA166593 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI LE, LU · 2012 to 2022
$3.7M
Credentialing next-generation human glioma models for precision therapeuticsR01CA258248 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Frank Furnari, Christopher Ryan Miller · 2022 to 2026
$3.0M
Developing Human Induced Pluripotent Stem Cell Precision Oncology ModelsR50CA233164 · NCI · WASHINGTON UNIVERSITY · PI Corina Anastasaki · 2018 to 2026
$1.2M
NCI NIH HHS CA258248NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA166593NCI NIH HHS R01 CA258248NCI NIH HHS R50 CA233164NCI NIH HHS U54 CA196519NINDS NIH HHS NS097211NINDS NIH HHS R35 NS097211
6 · The paper itself

Abstract

Nervous system tumors, particularly brain tumors, represent the most common tumors in children and one of the most lethal tumors in adults. Despite decades of research, there are few effective therapies for these cancers. Although human nervous system tumor cells and genetically engineered mouse models have served as excellent platforms for drug discovery and preclinical testing, they have limitations with respect to accurately recapitulating important aspects of the pathobiology of spontaneously arising human tumors. For this reason, attention has turned to the deployment of human stem cell engineering involving human embryonic or induced pluripotent stem cells, in which genetic alterations associated with nervous system cancers can be introduced. These stem cells can be used to create self-assembling three-dimensional cerebral organoids that preserve key features of the developing human brain. Moreover, stem cell-engineered lines are amenable to xenotransplantation into mice as a platform to investigate the tumor cell of origin, discover cancer evolutionary trajectories and identify therapeutic vulnerabilities. In this article, we review the current state of human stem cell models of nervous system tumors, discuss their advantages and disadvantages, and provide consensus recommendations for future research.

Indexed as

Brain NeoplasmsInduced Pluripotent Stem CellsAnimalsBrainCell DifferentiationChildHumansMiceMutationBrain tumorCRISPR engineeringhuman embryonic stem cells (hESCs)human induced pluripotent stem cells (hiPSCs)Nerve sheath tumors

Identifiers

PMID38353122
PMCPMC10886724
OpenAlexW4391815435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.